Suppr超能文献

面板测序显示原发性皮肤边缘区淋巴瘤中反复出现的 FAS 遗传改变。

Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma.

机构信息

Institute of Pathology, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

出版信息

J Invest Dermatol. 2018 Jul;138(7):1573-1581. doi: 10.1016/j.jid.2018.02.015. Epub 2018 Feb 23.

Abstract

Primary cutaneous marginal zone lymphoma (PCMZL) represents an indolent subtype of non-Hodgkin lymphoma that is clinically characterized by slowly growing skin tumors with a very low propensity for systemic dissemination. The underlying genetic basis of PCMZL has not been comprehensively elucidated. To gain deeper insight into the molecular pathogenesis of PCMZL, we performed hybridization-based panel sequencing of 38 patients with well-characterized PCMZL. In 32 of the 38 patients, we identified genetic alterations within 39 selected target genes. The most frequently detected alterations (24/38 patients, 63.2%) affected the FAS gene, of which 22 patients harbored alterations, which affect the functionally relevant death domain of the apoptosis-regulating FAS/CD95 protein in a dominant-negative manner. In addition, we identified highly recurrent mutations in three other genes, namely SLAMF1, SPEN, and NCOR2. Our molecular data suggest that apoptosis defects provide the molecular basis of the observed clinical features of PCMZL, which commonly presents with only slowly growing skin tumors, reflecting its invariably indolent behavior. From a diagnostic point of view, highly recurrent FAS mutations in PCMZL presumably separate this indolent lymphoma entity from pseudolymphoma, and this adds adjunctive discriminatory features at a molecular level.

摘要

原发性皮肤边缘区淋巴瘤(PCMZL)是一种惰性非霍奇金淋巴瘤亚型,其临床特征为生长缓慢的皮肤肿瘤,全身播散倾向极低。PCMZL 的潜在遗传基础尚未得到全面阐明。为了更深入地了解 PCMZL 的分子发病机制,我们对 38 例具有明确特征的 PCMZL 患者进行了基于杂交的panel 测序。在 38 例患者中的 32 例中,我们在 39 个选定的靶基因中发现了遗传改变。最常检测到的改变(24/38 例,63.2%)影响 FAS 基因,其中 22 例患者以显性负方式影响调节凋亡的 FAS/CD95 蛋白的功能相关死亡域。此外,我们还在另外三个基因中鉴定出高度复发的突变,即 SLAMF1、SPEN 和 NCOR2。我们的分子数据表明,凋亡缺陷为观察到的 PCMZL 临床特征提供了分子基础,PCMZL 通常仅表现为生长缓慢的皮肤肿瘤,反映其始终惰性的行为。从诊断的角度来看,PCMZL 中高度复发的 FAS 突变可能将这种惰性淋巴瘤实体与假性淋巴瘤区分开来,并在分子水平上增加辅助鉴别特征。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验